Methylphenidate and Sleep Difficulties in Children and Adolescents With ADHD : Results From the 2-Year Naturalistic Pharmacovigilance ADDUCE Study
OBJECTIVE: Short-term RCTs have demonstrated that MPH-treatment significantly reduces ADHD-symptoms, but is also associated with adverse events, including sleep problems. However, data on long-term effects of MPH on sleep remain limited.
METHODS: We performed a 2-year naturalistic prospective pharmacovigilance multicentre study. Participants were recruited into three groups: ADHD patients intending to start MPH-treatment (MPH-group), those not intending to use ADHD-medication (no-MPH-group), and a non-ADHD control-group. Sleep problems were assessed with the Children's-Sleep-Habits-Questionnaire (CSHQ).
RESULTS: 1,410 participants were enrolled. Baseline mean CSHQ-total-sleep-scores could be considered clinically significant for the MPH-group and the no-MPH-group, but not for controls. The only group to show a significant increase in any aspect of sleep from baseline to 24-months was the control-group. Comparing the MPH- to the no-MPH-group no differences in total-sleep-score changes were found.
CONCLUSION: Our findings support that sleep-problems are common in ADHD, but don't suggest significant negative long-term effects of MPH on sleep.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Journal of attention disorders - 28(2024), 5 vom: 31. März, Seite 699-707 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Häge, Alexander [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
207ZZ9QZ49 |
|---|
| Anmerkungen: |
Date Completed 12.03.2024 Date Revised 12.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/10870547241232337 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36879251X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36879251X | ||
| 003 | DE-627 | ||
| 005 | 20240312233932.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/10870547241232337 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1324.xml |
| 035 | |a (DE-627)NLM36879251X | ||
| 035 | |a (NLM)38389266 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Häge, Alexander |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Methylphenidate and Sleep Difficulties in Children and Adolescents With ADHD |b Results From the 2-Year Naturalistic Pharmacovigilance ADDUCE Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.03.2024 | ||
| 500 | |a Date Revised 12.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: Short-term RCTs have demonstrated that MPH-treatment significantly reduces ADHD-symptoms, but is also associated with adverse events, including sleep problems. However, data on long-term effects of MPH on sleep remain limited | ||
| 520 | |a METHODS: We performed a 2-year naturalistic prospective pharmacovigilance multicentre study. Participants were recruited into three groups: ADHD patients intending to start MPH-treatment (MPH-group), those not intending to use ADHD-medication (no-MPH-group), and a non-ADHD control-group. Sleep problems were assessed with the Children's-Sleep-Habits-Questionnaire (CSHQ) | ||
| 520 | |a RESULTS: 1,410 participants were enrolled. Baseline mean CSHQ-total-sleep-scores could be considered clinically significant for the MPH-group and the no-MPH-group, but not for controls. The only group to show a significant increase in any aspect of sleep from baseline to 24-months was the control-group. Comparing the MPH- to the no-MPH-group no differences in total-sleep-score changes were found | ||
| 520 | |a CONCLUSION: Our findings support that sleep-problems are common in ADHD, but don't suggest significant negative long-term effects of MPH on sleep | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ADHD | |
| 650 | 4 | |a long-term safety | |
| 650 | 4 | |a methylphenidate | |
| 650 | 4 | |a pharmacovigilance | |
| 650 | 4 | |a sleep problems | |
| 650 | 7 | |a Methylphenidate |2 NLM | |
| 650 | 7 | |a 207ZZ9QZ49 |2 NLM | |
| 650 | 7 | |a Central Nervous System Stimulants |2 NLM | |
| 700 | 1 | |a Man, Kenneth K C |e verfasserin |4 aut | |
| 700 | 1 | |a Inglis, Sarah K |e verfasserin |4 aut | |
| 700 | 1 | |a Buitelaar, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Carucci, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Danckaerts, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Dittmann, Ralf W |e verfasserin |4 aut | |
| 700 | 1 | |a Falissard, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Garas, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Hollis, Chris |e verfasserin |4 aut | |
| 700 | 1 | |a Konrad, Kerstin |e verfasserin |4 aut | |
| 700 | 1 | |a Kovshoff, Hanna |e verfasserin |4 aut | |
| 700 | 1 | |a Liddle, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a McCarthy, Suzanne |e verfasserin |4 aut | |
| 700 | 1 | |a Neubert, Antje |e verfasserin |4 aut | |
| 700 | 1 | |a Nagy, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Rosenthal, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Sonuga-Barke, Edmund J S |e verfasserin |4 aut | |
| 700 | 1 | |a Zuddas, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Ian C K |e verfasserin |4 aut | |
| 700 | 1 | |a Coghill, David |e verfasserin |4 aut | |
| 700 | 1 | |a Banaschewski, Tobias |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of attention disorders |d 1997 |g 28(2024), 5 vom: 31. März, Seite 699-707 |w (DE-627)NLM095560084 |x 1557-1246 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2024 |g number:5 |g day:31 |g month:03 |g pages:699-707 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/10870547241232337 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2024 |e 5 |b 31 |c 03 |h 699-707 | ||